- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04554927
Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer (WEBAPPAC)
July 31, 2023 updated by: Centre Francois Baclesse
The investigators hypothesize that the implementation of a Web-application in patients initiating adjuvant hormone therapy for breast cancer brings a benefit on treatment adherence and quality of life.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
438
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Caen, France, 14000
- Recruiting
- Centre Francois Baclesse
-
Contact:
- François GERNIER, Study nurse
- Phone Number: + 33 2 31 45 50 50
- Email: f.gernier@baclesse.unicancer.fr
-
Contact:
- Jean-Michel GRELLARD, project manager
- Phone Number: + 33 2 31 45 50 50
- Email: jm.grellard@baclesse.unicancer.fr
-
Principal Investigator:
- François GERNIER, Study nurse
-
Sub-Investigator:
- Gaelle ANNE, Study nurse
-
Sub-Investigator:
- Charlotte CEINTRE, Study nurse
-
Sub-Investigator:
- Rose-Marie CHARLES, Study nurse
-
Sub-Investigator:
- Emile GEORGE, MD
-
Sub-Investigator:
- Christelle LEVY, MD
-
Sub-Investigator:
- Adeline MOREL, MD
-
Sub-Investigator:
- Audrey FAVEYRIAL, MD
-
Sub-Investigator:
- Djelila ALLOUACHE, MD
-
Sub-Investigator:
- Julien GEFFRELOT, MD
-
Sub-Investigator:
- Carine SEGURA, MD
-
Sub-Investigator:
- Katharina GUNZER, MD
-
Sub-Investigator:
- Ioana HRAB, MD
-
Sub-Investigator:
- Alison JOHNSON, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient > 18 years old
- Breast cancer patient candidate for adjuvant hormone therapy
- Mastery of the French language
- Patient with a cell phone and an Internet connection
- Patient able to use a computer, smartphone, or tablet.
- Patient affiliated to a social security system
- Signing of informed consent prior to any specific study-related procedure
Exclusion Criteria:
- Patient who has previously received hormone therapy for cancer.
- Patient not trained in the use of the application
- Any associated medical or psychiatric condition that might compromise the patient's ability to participate in the study
- Patients with locoregional or metastatic recurrence
- Other history of cancer.
- Patient deprived of liberty, under guardianship or curatorship
- Simultaneous participation in a therapeutic clinical trial or other clinical study involving a connected tool
- Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: WEB-application
|
The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).
|
Active Comparator: Standard accompaniment
|
Personalized schedule of medical follow-up given to the patient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Observance of hormontherapy
Time Frame: 18 months
|
Evaluate the benefit of a web-based application on hormone therapy compliance (Morisky questionnary; answer Yes or No; 8 questions)
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life with self questionnaires
Time Frame: 18 months
|
Quality of life scores according (EORTC QLQ-C30 self-questionnaires ; minimum not at all to maximum Lot; 30 questions)
|
18 months
|
Quality of life with self questionnaires
Time Frame: 18 months
|
uality of life scores according (EORTC QLQ-BR23 self-questionnaires ; minimum not at all to maximum Lot; 23 questions)
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 3, 2020
Primary Completion (Estimated)
September 3, 2023
Study Completion (Estimated)
March 3, 2025
Study Registration Dates
First Submitted
September 14, 2020
First Submitted That Met QC Criteria
September 17, 2020
First Posted (Actual)
September 18, 2020
Study Record Updates
Last Update Posted (Actual)
August 1, 2023
Last Update Submitted That Met QC Criteria
July 31, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WEBAPPAC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on WEB-Application
-
University of California, San FranciscoWithdrawnLymphoma | Leukemia | Plasma Cell Dyscrasia
-
WepromCentre National de la Recherche Scientifique, France; Kelindi; Hospital of ToursCompleted
-
Ziekenhuis Oost-LimburgKU Leuven; TRACE: Centre For Translational Psychological ResearchUnknown
-
WepromKelindiCompletedPost Partum Depression | Child Development DisorderFrance
-
WepromKelindiRecruitingDevelopment, ChildFrance
-
WepromKelindiCompletedDevelopment, Child | Postnatal DepressionFrance
-
University of NottinghamCompleted
-
WepromAssistance Publique - Hôpitaux de Paris; Institut Pasteur; DOCAPOST; Direction...Completed
-
Zurich University of Applied SciencesHealth and Medical Services; Helsana; Neomentum; Sanatorium Kilchberg AG; Design...CompletedMental Health DisorderSwitzerland
-
Yale UniversityNational Institute of Mental Health (NIMH)Completed